A prospective randomized study of megestrol acetate and ibuprofen in gastrointestinal cancer patients with weight loss

D C McMillan; S J Wigmore; K C Fearon; P O'Gorman; C E Wright; C S McArdle

doi:10.1038/sj.bjc.6690077

A prospective randomized study of megestrol acetate and ibuprofen in gastrointestinal cancer patients with weight loss

D C McMillan, S J Wigmore, K C Fearon, P O'Gorman, C E Wright, C S McArdle

Deanery of Clinical Sciences

Research output: Contribution to journal › Article › peer-review

Abstract / Description of output

The use of megestrol acetate in the treatment of weight loss in gastrointestinal cancer patients has been disappointing. The aim of the present study was to compare the combination of megestrol acetate and placebo with megestrol acetate and ibuprofen in the treatment of weight loss in such patients. At baseline, 4-6 weeks and 12 weeks, patients underwent measurements of anthropometry, concentrations of albumin and C-reactive protein and assessment of appetite, performance status and quality of life using EuroQol-EQ-5D and EORTC QLQ-C30. Thirty-eight and 35 patients (median weight loss 18%) were randomized to megestrol acetate/placebo or megestrol acetate/ibuprofen, respectively, for 12 weeks. Forty-six (63%) of patients failed to complete the 12-week assessment. Of those evaluable at 12 weeks, there was a decrease in weight (median 2.8 kg) in the megestrol acetate/placebo group compared with an increase (median 2.3 kg) in the megestrol acetate/ibuprofen group (P

Original language	English
Pages (from-to)	495-500
Number of pages	6
Journal	British Journal of Cancer
Volume	79
Issue number	3-4
DOIs	https://doi.org/10.1038/sj.bjc.6690077
Publication status	Published - 1999

Access to Document

10.1038/sj.bjc.6690077

A prospective randomized study of megestrol acetate and ibuprofen in gastrointestinal cancer patients with weight loss
BJC Open. From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/
Final published version, 92.4 KBLicence: Creative Commons: Attribution-NonCommercial-ShareAlike (CC BY-NC-SA)

http://www.nature.com/bjc/journal/v79/n3/abs/6690077a.html

Cite this

@article{dca60fdc05b04c95908828ecc5a7bed5,

title = "A prospective randomized study of megestrol acetate and ibuprofen in gastrointestinal cancer patients with weight loss",

abstract = "The use of megestrol acetate in the treatment of weight loss in gastrointestinal cancer patients has been disappointing. The aim of the present study was to compare the combination of megestrol acetate and placebo with megestrol acetate and ibuprofen in the treatment of weight loss in such patients. At baseline, 4-6 weeks and 12 weeks, patients underwent measurements of anthropometry, concentrations of albumin and C-reactive protein and assessment of appetite, performance status and quality of life using EuroQol-EQ-5D and EORTC QLQ-C30. Thirty-eight and 35 patients (median weight loss 18%) were randomized to megestrol acetate/placebo or megestrol acetate/ibuprofen, respectively, for 12 weeks. Forty-six (63%) of patients failed to complete the 12-week assessment. Of those evaluable at 12 weeks, there was a decrease in weight (median 2.8 kg) in the megestrol acetate/placebo group compared with an increase (median 2.3 kg) in the megestrol acetate/ibuprofen group (P",

author = "McMillan, {D C} and Wigmore, {S J} and Fearon, {K C} and P O'Gorman and Wright, {C E} and McArdle, {C S}",

year = "1999",

doi = "10.1038/sj.bjc.6690077",

language = "English",

volume = "79",

pages = "495--500",

journal = "British Journal of Cancer",

issn = "0007-0920",

publisher = "Nature Publishing Group",

number = "3-4",

}

TY - JOUR

T1 - A prospective randomized study of megestrol acetate and ibuprofen in gastrointestinal cancer patients with weight loss

AU - McMillan, D C

AU - Wigmore, S J

AU - Fearon, K C

AU - O'Gorman, P

AU - Wright, C E

AU - McArdle, C S

PY - 1999

Y1 - 1999

N2 - The use of megestrol acetate in the treatment of weight loss in gastrointestinal cancer patients has been disappointing. The aim of the present study was to compare the combination of megestrol acetate and placebo with megestrol acetate and ibuprofen in the treatment of weight loss in such patients. At baseline, 4-6 weeks and 12 weeks, patients underwent measurements of anthropometry, concentrations of albumin and C-reactive protein and assessment of appetite, performance status and quality of life using EuroQol-EQ-5D and EORTC QLQ-C30. Thirty-eight and 35 patients (median weight loss 18%) were randomized to megestrol acetate/placebo or megestrol acetate/ibuprofen, respectively, for 12 weeks. Forty-six (63%) of patients failed to complete the 12-week assessment. Of those evaluable at 12 weeks, there was a decrease in weight (median 2.8 kg) in the megestrol acetate/placebo group compared with an increase (median 2.3 kg) in the megestrol acetate/ibuprofen group (P

AB - The use of megestrol acetate in the treatment of weight loss in gastrointestinal cancer patients has been disappointing. The aim of the present study was to compare the combination of megestrol acetate and placebo with megestrol acetate and ibuprofen in the treatment of weight loss in such patients. At baseline, 4-6 weeks and 12 weeks, patients underwent measurements of anthropometry, concentrations of albumin and C-reactive protein and assessment of appetite, performance status and quality of life using EuroQol-EQ-5D and EORTC QLQ-C30. Thirty-eight and 35 patients (median weight loss 18%) were randomized to megestrol acetate/placebo or megestrol acetate/ibuprofen, respectively, for 12 weeks. Forty-six (63%) of patients failed to complete the 12-week assessment. Of those evaluable at 12 weeks, there was a decrease in weight (median 2.8 kg) in the megestrol acetate/placebo group compared with an increase (median 2.3 kg) in the megestrol acetate/ibuprofen group (P

U2 - 10.1038/sj.bjc.6690077

DO - 10.1038/sj.bjc.6690077

M3 - Article

C2 - 10027319

SN - 0007-0920

VL - 79

SP - 495

EP - 500

JO - British Journal of Cancer

JF - British Journal of Cancer

IS - 3-4

ER -

A prospective randomized study of megestrol acetate and ibuprofen in gastrointestinal cancer patients with weight loss

Abstract / Description of output

Access to Document

Fingerprint

Cite this